Literature DB >> 17288891

Neuro-ophthalmologic Manifestations of Sarcoidosis.

Barney J Stern1, James Corbett.   

Abstract

The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-alpha antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.

Entities:  

Year:  2007        PMID: 17288891     DOI: 10.1007/s11940-007-0032-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  21 in total

1.  Refractory neurosarcoidosis responding to infliximab.

Authors:  J A Pettersen; D W Zochodne; R B Bell; L Martin; M D Hill
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

Review 2.  Neurosarcoidosis: a review of its intracranial manifestation.

Authors:  D A Nowak; D C Widenka
Journal:  J Neurol       Date:  2001-05       Impact factor: 4.849

Review 3.  Therapeutic options for sarcoidosis: new and old.

Authors:  Robert P Baughman
Journal:  Curr Opin Pulm Med       Date:  2002-09       Impact factor: 3.155

4.  Adalimumab for treatment of cutaneous sarcoidosis.

Authors:  Michael P Heffernan; David I Smith
Journal:  Arch Dermatol       Date:  2006-01

Review 5.  Neurologic manifestations of sarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

Review 6.  Neuro-ophthalmic complications of sarcoidosis.

Authors:  T Constantino; K Digre; P Zimmerman
Journal:  Semin Neurol       Date:  2000       Impact factor: 3.420

7.  Long-term follow-up of neurosarcoidosis.

Authors:  D Ferriby; J de Seze; T Stojkovic; E Hachulla; B Wallaert; A Destée; P Y Hatron; P Vermersch
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

8.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

9.  The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital.

Authors:  C J Johns; T M Michele
Journal:  Medicine (Baltimore)       Date:  1999-03       Impact factor: 1.889

10.  Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.

Authors:  Robert P Baughman; Elyse E Lower; Deborah A Bradley; Lawrence A Raymond; Adam Kaufman
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

View more
  2 in total

1.  Treating CNS sarcoidosis with infliximab and mycophenolate mofetil.

Authors:  James Corbett
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

2.  Neurosarcoidosis: unusual presentations and considerations for diagnosis and management.

Authors:  Walid Radwan; Brandon Lucke-Wold; Ibrahim Ahmed Robadi; Kymberly Gyure; Thomas Roberts; Sanjay Bhatia
Journal:  Postgrad Med J       Date:  2016-12-05       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.